P2X and P2Y Receptors
暂无分享,去创建一个
[1] J. Bajorath,et al. Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. , 2010, Journal of medicinal chemistry.
[2] K. Jacobson,et al. Quantification of Gi-Mediated Inhibition of Adenylyl Cyclase Activity Reveals That UDP Is a Potent Agonist of the Human P2Y14 Receptor , 2009, Molecular Pharmacology.
[3] Younis Baqi,et al. Interaction of New, Very Potent Non-Nucleotide Antagonists with Arg256 of the Human Platelet P2Y12 Receptor , 2009, Journal of Pharmacology and Experimental Therapeutics.
[4] E. Gouaux,et al. Crystal structure of the ATP-gated P2X4 ion channel in the closed state , 2009, Nature.
[5] C. Müller,et al. Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling. , 2009, Journal of medicinal chemistry.
[6] G. Reiser,et al. Structure and ligand-binding site characteristics of the human P2Y11 nucleotide receptor deduced from computational modelling and mutational analysis. , 2007, The Biochemical journal.
[7] Stefano Costanzi,et al. Defining the nucleotide binding sites of P2Y receptors using rhodopsin-based homology modeling , 2006, J. Comput. Aided Mol. Des..
[8] Eric A. Barnard,et al. International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy , 2006, Pharmacological Reviews.
[9] K. Jacobson,et al. (N)‐methanocarba‐2MeSADP (MRS2365) is a subtype‐specific agonist that induces rapid desensitization of the P2Y1 receptor of human platelets , 2006, Journal of thrombosis and haemostasis : JTH.
[10] K. Jacobson,et al. [32P]2‐iodo‐N6‐methyl‐(N)‐methanocarba‐2′‐deoxyadenosine‐3′,5′‐bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors , 2006, British journal of pharmacology.
[11] C. Müller,et al. Synthesis and preliminary evaluation of [3H]PSB-0413, a selective antagonist radioligand for platelet P2Y12 receptors. , 2005, Bioorganic & medicinal chemistry letters.
[12] J. Gever,et al. Discovery and Synthesis of a Novel and Selective Drug-Like P2X1 Antagonist. , 2005 .
[13] G. Schmalzing,et al. Synthesis and Structure−Activity Relationships of Suramin-Derived P2Y11 Receptor Antagonists with Nanomolar Potency , 2005 .
[14] G. Schmalzing,et al. Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist , 2005, Neuropharmacology.
[15] M. Williams,et al. [3H]A-317491, a Novel High-Affinity Non-Nucleotide Antagonist That Specifically Labels Human P2X2/3 and P2X3 Receptors , 2004, Journal of Pharmacology and Experimental Therapeutics.
[16] H. Nakata,et al. Hetero‐oligomerization between adenosine A1 and P2Y1 receptors in living cells: Formation of ATP‐sensitive adenosine receptors , 2003 .
[17] G. Schmalzing,et al. The suramin analogue NF279 is a novel and potent antagonist selective for the P2X1 receptor , 2000, Neuropharmacology.
[18] W. Stühmer,et al. Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors , 1999, Neuropharmacology.
[19] R. North,et al. Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. , 1998, Molecular pharmacology.
[20] K. Starke,et al. P2-purinoceptor antagonists: II. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to Evans blue and trypan blue , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.
[21] G. Reiser,et al. Hetero-oligomerization of the P2Y11 receptor with the P2Y1 receptor controls the internalization and ligand selectivity of the P2Y11 receptor. , 2008, The Biochemical journal.